200 related articles for article (PubMed ID: 27803062)
1. Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.
Klevorn LE; Berrien-Elliott MM; Yuan J; Kuehm LM; Felock GD; Crowe SA; Teague RM
Cancer Immunol Res; 2016 Dec; 4(12):1016-1026. PubMed ID: 27803062
[TBL] [Abstract][Full Text] [Related]
2. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
4. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.
Teague RM; Sather BD; Sacks JA; Huang MZ; Dossett ML; Morimoto J; Tan X; Sutton SE; Cooke MP; Ohlén C; Greenberg PD
Nat Med; 2006 Mar; 12(3):335-41. PubMed ID: 16474399
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.
Berrien-Elliott MM; Yuan J; Swier LE; Jackson SR; Chen CL; Donlin MJ; Teague RM
Cancer Immunol Res; 2015 Feb; 3(2):116-24. PubMed ID: 25516478
[TBL] [Abstract][Full Text] [Related]
7. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
8. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D; Khalili S; Dixit V; Kirk P; Chang T; Langowski J; Rubas W; Doberstein SK; Eldon M; Hoch U; Zalevsky J
PLoS One; 2017; 12(7):e0179431. PubMed ID: 28678791
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
[TBL] [Abstract][Full Text] [Related]
10. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
11. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
12. Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer.
Sierra RA; Thevenot P; Raber PL; Cui Y; Parsons C; Ochoa AC; Trillo-Tinoco J; Del Valle L; Rodriguez PC
Cancer Immunol Res; 2014 Aug; 2(8):800-11. PubMed ID: 24830414
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
14. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
15. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
16. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.
He LZ; Prostak N; Thomas LJ; Vitale L; Weidlick J; Crocker A; Pilsmaker CD; Round SM; Tutt A; Glennie MJ; Marsh H; Keler T
J Immunol; 2013 Oct; 191(8):4174-83. PubMed ID: 24026078
[TBL] [Abstract][Full Text] [Related]
17. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
18. Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.
Jackson SR; Berrien-Elliott M; Yuan J; Hsueh EC; Teague RM
PLoS One; 2014; 9(10):e110707. PubMed ID: 25343644
[TBL] [Abstract][Full Text] [Related]
19. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
[TBL] [Abstract][Full Text] [Related]
20. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
